Parkinson's Disease

The ELEGANCE study: levodopa-entacapone-carbidopa intestinal gel in Parkinson’s disease 1:13
The ELEGANCE study: levodopa-entacapone-carbidopa intestinal gel in Parkinson’s disease
K. Ray-Chaudhuri • 27 Jun 2022
Opicapone: an adjuvant to levodopa in PD therapy 4:28
Opicapone: an adjuvant to levodopa in PD therapy
Joaquim Ferreira • 26 Jun 2022
Final results of DUOGLOBE: real-world evidence for LGIC in advanced Parkinson’s disease 1:33
Final results of DUOGLOBE: real-world evidence for LGIC in advanced Parkinson’s disease
K. Ray-Chaudhuri • 27 Jun 2022
Neuropalliative care is an emerging subspecialty 2:15
Neuropalliative care is an emerging subspecialty
Robin Bessemer • 4 Apr 2022
Update on disease-modifying therapies in Parkinson’s disease 4:47
Update on disease-modifying therapies in Parkinson’s disease
Angelo Antonini • 26 Jun 2022
Opicapone versus entacapone for early morning dystonia in Parkinson’s disease 2:31
Opicapone versus entacapone for early morning dystonia in Parkinson’s disease
Fabrizio Stocchi • 25 Jun 2022
Latest approaches to improve the delivery of levodopa 2:32
Latest approaches to improve the delivery of levodopa
Fabrizio Stocchi • 25 Jun 2022
The biological definition of Parkinson’s disease 1:43
The biological definition of Parkinson’s disease
Tiago Outeiro • 25 Jun 2022
The clinical benefit of safinamide in treating Parkinson’s disease 1:46
The clinical benefit of safinamide in treating Parkinson’s disease
Angelo Antonini • 29 Mar 2022
The 5-2-1 screening criteria and other advances in Parkinson’s disease 3:41
The 5-2-1 screening criteria and other advances in Parkinson’s disease
Angelo Antonini • 29 Mar 2022
The impact of COVID-19 on palliative care in Parkinson’s disease 2:49
The impact of COVID-19 on palliative care in Parkinson’s disease
Angelo Antonini • 29 Mar 2022
COMT inhibitors for motor fluctuations in Parkinson’s disease 1:18
COMT inhibitors for motor fluctuations in Parkinson’s disease
Heinz Reichmann • 22 Mar 2022
Advances in the genetics of Parkinson’s disease 4:53
Advances in the genetics of Parkinson’s disease
Heinz Reichmann • 22 Mar 2022
Progress in the management of non-motor symptoms of Parkinson’s disease 1:47
Progress in the management of non-motor symptoms of Parkinson’s disease
Heinz Reichmann • 22 Mar 2022
Alpha-synuclein inhibitors, kinase inhibitors & targeting mitochondria in Parkinson’s disease 2:05
Alpha-synuclein inhibitors, kinase inhibitors & targeting mitochondria in Parkinson’s disease
Heinz Reichmann • 22 Mar 2022
Complex symptom burden in atypical parkinsonism 1:16
Complex symptom burden in atypical parkinsonism
Robin Bessemer • 4 Apr 2022
The content of VJNeurology is intended for healthcare professionals